1st Quarter - Termination — CEPHEID for CEPHEID (2017)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$25,000

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Jan 26, 2017

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
1st Quarter - Termination (this page)	May 11, 2017	$25,000	Replaced
1st Quarter - Report	May 11, 2017	$12,300	Replaced
1st Quarter - Termination Amendment	Mar 23, 2018	$12,300	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

IVD regulation reform, antimicrobial resistance policies, CMS coverage and ;payment issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

CMS coverage determination process, delay in PAMA implementation

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Disease Control & Prevention (CDC); White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS)

Medical/Disease Research/Clinical Labs MED

IVD regulatory reform, CMS coverage determination process

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; SENATE; Veterans Affairs, Dept of (VA); White House Office; Health & Human Services, Dept of (HHS)

Science/Technology SCI

IVD regulatory reform, point of care testing

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.